CA Patent

CA2597889C — Aptamer therapeutics useful in the treatment of complement-related disorders

Assigned to Iveric Bio Inc · Expires 2015-11-10 · 11y expired

What this patent protects

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

USPTO Abstract

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

Patent Metadata

Patent number: CA2597889C
Jurisdiction: CA
Classification: —
Expires: 2015-11-10
Drug substance claim: No
Drug product claim: No
Assignee: Iveric Bio Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.